Basilea PharmaceuticaXSWX:BSLN +2.26%61 Days Inventory is 267.12 as of Dec. 2025, which is 18% below its 10-year median of 326.20. GuruFocus rates XSWX:BSLN with a GF Score™ of 61/100 and a GF Value™ of CHF57.51 (Fairly Valued). The stock has 2 warning signs investors should review. Among 638 Biotechnology companies, Basilea Pharmaceutica ranks worse than 59.25% on this metric.
The historical rank and industry rank for Basilea Pharmaceutica's Days Inventory or its related term are showing as below:
XSWX:BSLN'
s Days Inventory Range Over the Past 10 Years
Min: 234.5 Med: 326.2 Max: 836.56
Current: 234.5
During the past 13 years, Basilea Pharmaceutica's highest Days Inventory was 836.56. The lowest was 234.50. And the median was 326.20.
XSWX:BSLN's Days Inventory is ranked worse than 59.25% of 638
companies
in the Biotechnology industry
Industry Median: 183.875
vs XSWX:BSLN: 234.50
Basilea Pharmaceutica's Days Inventory
declined
from Dec. 2024 (279.50) to Dec. 2025 (267.12).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Basilea Pharmaceutica's Inventory Turnover for the
six
months ended in Dec. 2025 was 0.68.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Basilea Pharmaceutica's Inventory-to-Revenue for the
six
months ended in Dec. 2025 was 0.17.
Basilea Pharmaceutica (XSWX:BSLN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Basilea Pharmaceutica's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Basilea Pharmaceutica's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Basilea Pharmaceutica Days Inventory Related Terms
Basilea Pharmaceutica Days Inventory Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Days Inventory Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Days Inventory distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a Days Inventory of 267.12 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Basilea Pharmaceutica and its competitors. This is 18% below median its historical median of 326.20. Over the past decade, Basilea Pharmaceutica's Days Inventory has ranged from 234.50 to 836.56. According to the industry distribution chart, Basilea Pharmaceutica ranks #378 out of 638 companies in the Biotechnology industry, placing it in the top 59.2%.
Is Basilea Pharmaceutica's Days Inventory too high?
Basilea Pharmaceutica's current Days Inventory of 267.12 is 18% below median its 10-year median of 326.20. Over the past 10 years, this metric has ranged from a low of 234.50 to a high of 836.56. The Biotechnology industry median Days Inventory is 183.88. Basilea Pharmaceutica's value of 267.12 is 45.3% above this industry median. Based on the distribution chart, Basilea Pharmaceutica ranks #378 out of 638 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #378 out of 638 companies for Days Inventory. This places Basilea Pharmaceutica in the lower half of its industry. The industry median Days Inventory is 183.88. Basilea Pharmaceutica's value of 267.12 is 45.3% above this benchmark. Historically, Basilea Pharmaceutica's own Days Inventory has ranged from 234.50 to 836.56 over the past decade. While the company's 10-year median is 326.20 vs. the industry median of 183.88, Basilea Pharmaceutica has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.88, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Basilea Pharmaceutica's current Days Inventory of 267.12 is 45.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Days Inventory is 183.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Days Inventory is 267.12, which is 18% below median its own 10-year median of 326.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.51, compared to a current price of CHF54.30 — trading 5.6% below its estimated fair value. The current Days Inventory is 267.12, which is 18% below median its 10-year median of 326.20 and 45.3% above the Biotechnology industry median of 183.88. Basilea Pharmaceutica's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Days Inventory is 267.12 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF54.30 is trading 5.6% below its estimated GF Value™ of CHF57.51.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
Days Inventory: 267.12 (18% below median its 10-year median of 326.20)
GF Value™: CHF57.51 vs. price of CHF54.30 (5.6% below fair value)
Industry Position: 45.3% above the Biotechnology median (#378 of 638)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
61GF Score
Get the complete analysis for XSWX:BSLN
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
